HealthSOPHiA Genetics and Myriad to develop genomic test for targeted prostate cancer care
SOPHiA Genetics and Myriad Genetics have agreed to work together on PrGIS, a biomarker that measures genomic instability in prostate cancer cells, to test it in clinical trials and make it available in local laboratories around the world.